Teva Pharmaceutical Industries, Ltd.: Multiple Sclerosis trials
The registry lists 26 Multiple Sclerosis studies with Teva Pharmaceutical Industries, Ltd. as lead sponsor. 0 are open to participants now and 12 have results posted.
Phase 1 2Phase 2 7Phase 3 9Phase 4 6No phase 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone®CompletedNCT02499900Phase 4Results posted
- A Phase 2 Clinical Study in Subjects With Primary Progressive Multiple Sclerosis to Assess the Efficacy, Safety and Tolerability of Two Oral Doses of Laquinimod Either of 0.6 mg/Day or 1.5mg/Day (Experimental Drug) as Compared to PlaceboCompletedNCT02284568Phase 2Results posted
- Safety and Tolerability of Glatiramer AcetateCompletedNCT01874145Phase 3Results posted
- The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)CompletedNCT01707992Phase 3Results posted
- Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) PatientsCompletedNCT01167426Phase 3Results posted
- A Study to Evaluate the Long-term Safety, Tolerability and Effect of Daily Oral Laquinimod 0.6 mg on Disease Course in Subjects With Relapsing Multiple SclerosisTerminatedNCT01047319Phase 3Results posted
- A Study To Evaluate the Long-Term Safety, Tolerability and Effect on Disease CourseTerminatedNCT00988052Phase 3Results posted
- Safety of New Formulation of Glatiramer AcetateCompletedNCT00947752Phase 3Results posted
- Evaluate Early Glatiramer Acetate Treatment in Delaying Conversion to Clinically Definite Multiple Sclerosis of Subjects Presenting With Clinically Isolated SyndromeCompletedNCT00666224Phase 3Results posted
- BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)CompletedNCT00605215Phase 3Results posted
- Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)CompletedNCT00509145Phase 3Results posted
- Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer AcetateTerminatedNCT00203047Phase 4Results posted
- Copaxone Subcutaneous Injection Syringe Special Drug Use-Result Investigation (All-Case Investigation) "Prevention of Relapse of Multiple Sclerosis"CompletedNCT03209479
- A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and TolerabilityWithdrawnNCT01404117Phase 2
- Therapy Optimization in Multiple Sclerosis (MS)CompletedNCT00819000
- One Year Extension Study To Protocol C2/5/TZ:MS-05TerminatedNCT00464958Phase 1/2
- Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant SpasticityCompletedNCT00358293Phase 1/2
- Determine Impact of Multiple NAb Tests on Treatment Compared to Usual Care of MS Patients on High-dose IFN TherapyCompletedNCT00336557
- A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Taking an Antihistamine (Zyrtec®) or Placebo Prior to Daily Injections of Copaxone®.CompletedNCT00240032Phase 4
- A Study Comparing Shared Solutions® Plus MS Center Support Versus Shared Solutions® AloneCompletedNCT00240006Phase 4
- A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®CompletedNCT00239993Phase 4
- A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® TherapyCompletedNCT00238654
- A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Using Alcohol Wipes Prior to Daily Injections of Copaxone®.CompletedNCT00220922Phase 4
- Safety and Efficacy Study of Copaxone Administered in Combination With MinocyclineCompletedNCT00203112Phase 2
- Safety and Efficacy Study of Copaxone Administered in Combination With N-AcetylcysteineCompletedNCT00203099Phase 2
- A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved DoseCompletedNCT00202982Phase 2